Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products

1. An acellular delipidized biocompatible biomaterial comprising a mammalian adipose tissue extracellular matrix (ECM) derived from cadaveric adipose tissue, the biomaterial having between 1% to 0.001% adipose lipid by weight and a complex viscosity of 1×10 4 to 9×10 5 Pas, wherein the biomaterial is non-inflammatory when implanted.

2. The biomaterial of claim 1 , wherein the complex viscosity is 1×10 4 to 8×10 5 Pas.

3. The biomaterial of claim 1 , wherein the complex viscosity is 1×10 4 to 3×10 5 Pas.

4. The biomaterial of claim 1 , further comprising a cross-linking agent.

5. The biomaterial of claim 4 , wherein the cross-linking agent is selected from the group consisting of carbodiimide (EDC), hexamethylene diisocyanate (HMDC), gluteraldehyde, proanthocyanidin, ribose, threose, and lysyl oxidase, carbodiimide, polyepoxy ethers, divinyl sulfone (DVS), genipin, polyaldehyde and diphenylphosphoryl azide (DPPA), genipin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimidate, carbodiimides, succinimidyls, diisocyanates, and acyl azide.

6. The biomaterial of claim 1 , wherein the biomaterial is injectable.

7. The biomaterial of claim 1 , wherein the biomaterial is sterilized.

8. An acellular delipidized biocompatible biomaterial comprising a mammalian adipose tissue extracellular matrix (ECM) derived from cadaveric adipose tissue, the biomaterial having between 1% to 0.001% adipose lipid by weight and a complex modulus of 5×10 3 to 1×10 5 Pa, wherein the biomaterial is non-inflammatory when implanted.

9. The biomaterial of claim 8 , wherein the complex modulus is 1×10 4 to 1×10 5 Pa.

10. The biomaterial of claim 8 , wherein the complex modulus is 1×10 4 to 9×10 4 Pa.

11. The biomaterial of claim 8 , further comprising a cross-linking agent.

12. The biomaterial of claim 11 , wherein the cross-linking agent is selected from the group consisting of carbodiimide (EDC), hexamethylene diisocyanate (HMDC), gluteraldehyde, proanthocyanidin, ribose, threose, and lysyl oxidase, carbodiimide, polyepoxy ethers, divinyl sulfone (DVS), genipin, polyaldehyde and diphenylphosphoryl azide (DPPA), genipin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimidate, carbodiimides, succinimidyls, diisocyanates, and acyl azide.

13. The biomaterial of claim 8 , wherein the biomaterial is injectable.

14. An acellular delipidized biocompatible biomaterial comprising a mammalian adipose tissue extracellular matrix (ECM) derived from cadaveric adipose tissue, the biomaterial having between 1% to 0.001% adipose lipid by weight and an elastic modulus of 5×10 3 to 1×10 5 Pa, wherein the biomaterial is non-inflammatory when implanted.

15. The biomaterial of claim 14 , wherein the elastic modulus is 1×10 4 to 1×10 5 Pa.

16. The biomaterial of claim 14 , wherein the elastic modulus is 1×10 4 to 9×10 4 Pa.

17. The biomaterial of claim 14 , further comprising a cross-linking agent.

18. The biomaterial of claim 17 , wherein the cross-linking agent is selected from the group consisting of carbodiimide (EDC), hexamethylene diisocyanate (HMDC), gluteraldehyde, proanthocyanidin, ribose, threose, and lysyl oxidase, carbodiimide, polyepoxy ethers, divinyl sulfone (DVS), genipin, polyaldehyde and diphenylphosphoryl azide (DPPA), genipin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimidate, carbodiimides, succinimidyls, diisocyanates, and acyl azide.

19. The biomaterial of claim 14 , wherein the biomaterial is injectable.

20. An acellular delipidized biocompatible biomaterial comprising a mammalian adipose tissue extracellular matrix (ECM) derived from cadaveric adipose tissue, the biomaterial having between 1% to 0.001% adipose lipid by weight and a viscous modulus of 5×10 3 to 1×10 5 Pa, wherein the biomaterial is non-inflammatory when implanted.

21. The biomaterial of claim 20 , wherein the viscous modulus is 1×10 4 to 1×10 5 Pa.

22. The biomaterial of claim 20 , wherein the viscous modulus is 1×10 4 to 9×10 4 Pa.

23. The biomaterial of claim 20 , further comprising a cross-linking agent.

24. The biomaterial of claim 23 , wherein the cross-linking agent is selected from the group consisting of carbodiimide (EDC), hexamethylene diisocyanate (HMDC), gluteraldehyde, proanthocyanidin, ribose, threose, and lysyl oxidase, carbodiimide, polyepoxy ethers, divinyl sulfone (DVS), genipin, polyaldehyde and diphenylphosphoryl azide (DPPA), genipin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimidate, carbodiimides, succinimidyls, diisocyanates, and acyl azide.

25. The biomaterial of claim 20 , wherein the biomaterial is injectable.

26. An acellular delipidized biocompatible biomaterial comprising a mammalian adipose tissue extracellular matrix (ECM) derived from cadaveric adipose tissue, the biomaterial having between 1% to 0.001% adipose lipid by weight and a tan (δ) of 0.05 to 2.0, wherein the biomaterial is non-inflammatory when implanted.

27. The biomaterial of claim 26 , wherein the tan (δ) is 0.1 to 1.0.

28. The biomaterial of claim 26 , wherein the tan (δ) of 0.1 to 0.75.

29. The biomaterial of claim 26 , further comprising a cross-linking agent.

30. The biomaterial of claim 29 , wherein the cross-linking agent is selected from the group consisting of carbodiimide (EDC), hexamethylene diisocyanate (HMDC), gluteraldehyde, proanthocyanidin, ribose, threose, and lysyl oxidase, carbodiimide, polyepoxy ethers, divinyl sulfone (DVS), genipin, polyaldehyde and diphenylphosphoryl azide (DPPA), genipin, epoxy compounds, dialdehyde starch, glutaraldehyde, formaldehyde, dimethyl suberimidate, carbodiimides, succinimidyls, diisocyanates, and acyl azide.

31. The biomaterial of claim 26 , wherein the biomaterial is injectable.

32. A composition comprising at least one biomaterial of claim 1 and at least one pharmaceutically acceptable carrier or adjuvant.

33. A composition comprising at least one biomaterial of claim 8 and at least one pharmaceutically acceptable carrier or adjuvant.

34. A composition comprising at least one biomaterial of claim 14 and at least one pharmaceutically acceptable carrier or adjuvant.

35. A composition comprising at least one biomaterial of claim 20 and at least one pharmaceutically acceptable carrier or adjuvant.

36. A composition comprising at least one biomaterial of claim 26 and at least one pharmaceutically acceptable carrier or adjuvant.